Literature DB >> 9056055

The analgesic tramadol has minimal effect on gastrointestinal motor function.

C H Wilder-Smith1, A Bettiga.   

Abstract

AIMS: The analgesic tramadol, an opioid agonist and monoaminergic reuptake blocker, has been assumed to interfere less with gastrointestinal motor function than other opioid analgesics, but this has not been specifically investigated. In this study we examined the effect of tramadol on variables of gastrointestinal motor function.
METHODS: Ten healthy volunteers participated in a two-arm, placebo-controlled, double-blind, randomized, cross-over study comparing tramadol 50 mg and placebo solutions given four times a day for 10 days. Oro-caecal (lactulose H2-breath test) and colonic (solid markers) transit times and anal sphincter pressures were measured after 10 days dosing.
RESULTS: Median oro-caecal transit time was 90 min (interquartile range: 75-105) with placebo and 90 min (60-105) with tramadol (not significant). The median total colonic transit time increased from 45.6 h (25.2-64.8) with placebo to 58.8 h (50.4-78.0) with tramadol (not significant), which is still within the normal range (< 60 h). Anal sphincter resting pressures were not significantly changed by tramadol compared with placebo.
CONCLUSIONS: Tramadol has a minor delaying effect on colonic transit, but no effect on upper gastrointestinal transit or gut smooth muscle tone. Tramadol may be a useful analgesic where interference with gut motor function is undesirable.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9056055     DOI: 10.1111/j.1365-2125.1997.tb00035.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  16 in total

Review 1.  Management of opioid-induced bowel dysfunction in cancer patients.

Authors:  Antonio Cesar Tamayo; Paola Andrea Diaz-Zuluaga
Journal:  Support Care Cancer       Date:  2004-09       Impact factor: 3.603

Review 2.  The role of tramadol in cancer pain treatment--a review.

Authors:  Wojciech Leppert; Jacek Łuczak
Journal:  Support Care Cancer       Date:  2004-11-18       Impact factor: 3.603

3.  Effect of tramadol and morphine on pain and gastrointestinal motor function in patients with chronic pancreatitis.

Authors:  C H Wilder-Smith; L Hill; W Osler; S O'Keefe
Journal:  Dig Dis Sci       Date:  1999-06       Impact factor: 3.199

Review 4.  Clinical pharmacology of tramadol.

Authors:  Stefan Grond; Armin Sablotzki
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 5.  Tramadol: a review of its use in perioperative pain.

Authors:  L J Scott; C M Perry
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

6.  A randomized, double-blind, crossover comparison of the efficacy and safety of oral controlled-release tramadol and placebo in patients with painful osteoarthritis.

Authors:  C Thorne; A D Beaulieu; D J Callaghan; W F O'Mahony; J M Bartlett; R Knight; G R Kraag; R Akhras; P S Piraino; J Eisenhoffer; Z Harsanyi; A C Darke
Journal:  Pain Res Manag       Date:  2008 Mar-Apr       Impact factor: 3.037

7.  Once-daily, controlled-release tramadol and sustained-release diclofenac relieve chronic pain due to osteoarthritis: a randomized controlled trial.

Authors:  A D Beaulieu; P M Peloso; B Haraoui; W Bensen; G Thomson; J Wade; P Quigley; J Eisenhoffer; Z Harsanyi; A C Darke
Journal:  Pain Res Manag       Date:  2008 Mar-Apr       Impact factor: 3.037

8.  Pharmacokinetic evaluation of a new oral sustained release dosage form of tramadol.

Authors:  H Malonne; B Sonet; B Streel; S Lebrun; S De Niet; A Sereno; F Vanderbist
Journal:  Br J Clin Pharmacol       Date:  2004-03       Impact factor: 4.335

Review 9.  Pain in terminally ill patients: guidelines for pharmacological management.

Authors:  Jay R Thomas; Charles F von Gunten
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 10.  Pain treatment in multimorbid patients, the older population and other high-risk groups. The clinical challenge of reducing toxicity.

Authors:  C H Wilder-Smith
Journal:  Drug Saf       Date:  1998-06       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.